Curbstone Financial Management Corp Has $993,000 Holdings in Bristol-Myers Squibb Co (NYSE:BMY)

Curbstone Financial Management Corp lifted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 2.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,584 shares of the biopharmaceutical company’s stock after purchasing an additional 500 shares during the period. Curbstone Financial Management Corp’s holdings in Bristol-Myers Squibb were worth $993,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the company. Biechele Royce Advisors lifted its holdings in shares of Bristol-Myers Squibb by 5.1% during the third quarter. Biechele Royce Advisors now owns 60,967 shares of the biopharmaceutical company’s stock worth $3,092,000 after purchasing an additional 2,952 shares during the period. Kistler Tiffany Companies LLC lifted its holdings in shares of Bristol-Myers Squibb by 5.3% during the third quarter. Kistler Tiffany Companies LLC now owns 11,796 shares of the biopharmaceutical company’s stock worth $598,000 after purchasing an additional 590 shares during the period. Iowa State Bank lifted its holdings in shares of Bristol-Myers Squibb by 5.7% during the third quarter. Iowa State Bank now owns 57,625 shares of the biopharmaceutical company’s stock worth $2,922,000 after purchasing an additional 3,089 shares during the period. Moody National Bank Trust Division lifted its holdings in shares of Bristol-Myers Squibb by 130.4% during the third quarter. Moody National Bank Trust Division now owns 12,388 shares of the biopharmaceutical company’s stock worth $628,000 after purchasing an additional 7,012 shares during the period. Finally, Sigma Investment Counselors Inc. lifted its holdings in shares of Bristol-Myers Squibb by 19.0% during the third quarter. Sigma Investment Counselors Inc. now owns 49,440 shares of the biopharmaceutical company’s stock worth $2,507,000 after purchasing an additional 7,901 shares during the period. Institutional investors own 80.25% of the company’s stock.

In related news, Director Robert J. Bertolini purchased 11,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was purchased at an average cost of $44.72 per share, with a total value of $491,920.00. Following the completion of the purchase, the director now owns 11,397 shares in the company, valued at approximately $509,673.84. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.13% of the company’s stock.

BMY opened at $53.03 on Friday. Bristol-Myers Squibb Co has a 1-year low of $42.48 and a 1-year high of $55.85. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51. The company has a market cap of $85.75 billion, a P/E ratio of 13.32, a price-to-earnings-growth ratio of 1.23 and a beta of 0.72. The company has a fifty day moving average price of $49.95 and a two-hundred day moving average price of $47.19.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 25th. The biopharmaceutical company reported $1.18 earnings per share for the quarter, beating the consensus estimate of $1.06 by $0.12. Bristol-Myers Squibb had a net margin of 26.14% and a return on equity of 47.63%. The firm had revenue of $6.27 billion during the quarter, compared to the consensus estimate of $6.10 billion. During the same period in the previous year, the firm posted $1.01 earnings per share. The business’s revenue was up 10.0% compared to the same quarter last year. On average, research analysts forecast that Bristol-Myers Squibb Co will post 4.28 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a $0.41 dividend. This represents a $1.64 annualized dividend and a yield of 3.09%. The ex-dividend date of this dividend is Thursday, October 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 41.21%.

A number of brokerages recently weighed in on BMY. Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 target price for the company in a research note on Wednesday, August 14th. JPMorgan Chase & Co. set a $62.00 target price on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Friday, September 13th. TheStreet raised shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research note on Wednesday, September 18th. Bank of America began coverage on shares of Bristol-Myers Squibb in a research note on Wednesday. They set a “buy” rating and a $60.00 target price for the company. Finally, ValuEngine downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Buy” and an average price target of $56.53.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.